|
spondyloarthritis |
13 |
|
inflammation |
10 |
|
rheumatoid arthritis |
10 |
|
atherosclerosis |
8 |
|
cardiovascular diseases |
8 |
|
imaging |
8 |
|
multi-detector computed tomography |
8 |
|
axial spondyloarthritis |
7 |
|
endothelial progenitor cells |
7 |
|
eq-5d |
7 |
|
hrqol |
7 |
|
rheumatoid |
7 |
|
spa |
7 |
|
arthritisosteogenesis |
6 |
|
bone–vascular axis |
6 |
|
calcification |
6 |
|
conduction disorders |
6 |
|
coronary artery disease |
6 |
|
osteocalcin |
6 |
|
osteogenic endothelial progenitor cells |
6 |
|
allergy |
5 |
|
cardiovascular event |
5 |
|
cerebrovascular event |
5 |
|
coronary artery calcium |
5 |
|
drug |
5 |
|
hypersensitivity |
5 |
|
mri |
5 |
|
myocardial infarction |
5 |
|
peripheral artery disease |
5 |
|
prevalence |
5 |
|
rheumatology |
5 |
|
stroke |
5 |
|
ankylosing spondylitis |
4 |
|
asas criteria |
4 |
|
carotid intima-media thickness |
4 |
|
corner inflammatory lesion |
4 |
|
diagnosis |
4 |
|
epidemiology |
4 |
|
fungal |
4 |
|
high-sensitivity troponin i |
4 |
|
inflammatory bowel disease |
4 |
|
left ventricular function |
4 |
|
left ventricular longitudinal strain |
4 |
|
major adverse cardiovascular events |
4 |
|
malignancy |
4 |
|
modified new york criteria |
4 |
|
mortality |
4 |
|
pneumonia |
4 |
|
prophylaxis |
4 |
|
thiopurines |
4 |
|
uveitis |
4 |
|
age |
3 |
|
ankylosing spondylitis disease activity index |
3 |
|
antirheumatic agents |
3 |
|
apparent weighted coefficient |
3 |
|
ascending |
3 |
|
biologics |
3 |
|
cervical cancer |
3 |
|
community-acquired pneumonia |
3 |
|
dermatomyositis |
3 |
|
diffusion-weighted imaging |
3 |
|
disease modifying anti-rheumatic drugs |
3 |
|
glucocorticoid |
3 |
|
incidence |
3 |
|
infliximab |
3 |
|
interstitial lung disease |
3 |
|
mda5 |
3 |
|
pneumomediastinum |
3 |
|
risk |
3 |
|
short tau inversion recovery sequence |
3 |
|
smoking |
3 |
|
spondyloarthritis research consortium of canada mri |
3 |
|
steroid |
3 |
|
tuberculosis |
3 |
|
anxiety disorder |
2 |
|
arthritis |
2 |
|
back pain |
2 |
|
bath ankylosing spondylitis metrology index |
2 |
|
depressive disorder |
2 |
|
disease activity |
2 |
|
dmard |
2 |
|
fatigue |
2 |
|
herpes zoster |
2 |
|
hospital anxiety and depression scale |
2 |
|
losing spondylitis spine score |
2 |
|
magnetic resonance imaging |
2 |
|
methotrexate |
2 |
|
modified stoke anky |
2 |
|
psoriatic arthritis |
2 |
|
risk factors |
2 |
|
short tau inversion recovery (stir) image |
2 |
|
skin psoriasis |
2 |
|
spinal mobility |
2 |
|
spine |
2 |
|
spondyloarthropathies |
2 |
|
systemic lupus erythematosus |
2 |
|
antidiabetic agent |
1 |
|
azathioprine |
1 |
|
basdai |
1 |
|
biguanide |
1 |
|
crp |
1 |
|
cytokine storm syndrome |
1 |
|
drug-induced |
1 |
|
granulocyte colony-stimulating factor |
1 |
|
immune checkpoint inhibitors |
1 |
|
immune-related adverse events |
1 |
|
immunotherapy |
1 |
|
iraes |
1 |
|
lactic acidosis |
1 |
|
leucopenia |
1 |
|
metformin |
1 |
|
metformin-associated lactic acidosis |
1 |
|
mobility |
1 |
|
poisoning |
1 |
|
toxicology |
1 |
|
ulcerative colitis |
1 |
